中等厚度黑色素瘤:基于人群的手术质量指标研究
基于2004至2018年监测、流行病学和最终结果数据,分析66,319例T2/T3期黑色素瘤患者淋巴结手术的指南依从性,发现28.8%未接受淋巴结手术,临床淋巴结阴性患者前哨淋巴结活检率为63.7%,淋巴结清扫率从2004年至2018年下降,依从性与年轻、男性、肿瘤有丝分裂率及部位相关,并改善5年癌症特异性生存(90.0% vs 83.4%)。
要点
- 66,319例T2/T3期患者中28.8%未接受淋巴结手术。
- 临床淋巴结阴性患者中63.7%接受前哨淋巴结活检。
- 依从性与年轻、男性、肿瘤有丝分裂率及部位(四肢>躯干/头颈)相关。
核心结论
- 尽管有明确指南,近期队列中约三分之一中等厚度黑色素瘤患者未接受推荐的淋巴结手术。
- 淋巴结状态是辅助全身治疗相对获益及病理淋巴结阳性/临床淋巴结阴性患者主动监测需求的关键决定因素。
- 这些数据凸显了临床护理差距,改善指南依从性是改善中等厚度黑色素瘤患者癌症结局的合理策略。
研究设计与样本
- 基于人群的研究,利用2004年至2018年监测、流行病学和最终结果(SEER)数据。
- 纳入T2/T3期且转移为0的黑色素瘤病例。
- 分析采用Cochran-Armitage趋势检验、多变量逻辑回归和Kaplan-Meier生存估计。
主要发现
- 66,319例符合条件的T2/T3期患者中,57,211例临床淋巴结阴性,2,191例临床淋巴结阳性,6,197例临床淋巴结未报告,19,044/66,319(28.8%)未接受淋巴结手术。
- 临床淋巴结阴性患者中,36,433例(63.7%)接受前哨淋巴结活检,31,026例(85.2%)病理淋巴结阴性;临床淋巴结阳性患者中1,499例(68.4%)接受淋巴结清扫。
- 2004年至2018年,临床淋巴结阴性/病理淋巴结阳性患者的淋巴结清扫率从79.8%降至32.0%,临床淋巴结阳性/病理淋巴结阳性患者从80.4%降至61.2%(均P < .0001)。
- 临床淋巴结阴性患者的淋巴结手术依从性从2004年63.7%改善至2018年70.4%(P < .0001)。
- 多变量分析中依从性与年轻年龄、男性、肿瘤有丝分裂率及部位(四肢>躯干/头颈)相关,并改善5年癌症特异性生存(90.0% vs 83.4%)(均P < .0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Variability in guideline compliance for melanoma lymph node surgery is partially attributable to controversy about patient selection. Prior data has indicated suboptimal practice of sentinel lymph node biopsy and undertreatment of clinically node-positive disease, predating Multicenter Selective Lymphadenectomy Trial II publication. To minimize bias, we studied compliance with lymph node surgery guidelines in T2/T3 (intermediate-thickness) melanoma patients, where the greatest agreement exists. METHODS: T2/T3 and metastasis 0 melanoma cases were identified from 2004 to 2018 Surveillance, Epidemiology, and End Results data. Analysis used Cochran-Armitage test for trends, multivariable logistic regression, and Kaplan-Meier survival estimates. RESULTS: Of 66,319 eligible T2/T3 patients, 57,211 were clinically node negative; 2,191 were clinically node positive; 6,197 were clinical node unreported; and 19,044/66,319 (28.8%) had no lymph node surgery. Among clinically node-negative patients, 36,433 (63.7%) underwent sentinel lymph node biopsy and 31,026 (85.2%) were pathologically node negative; 1,499 clinically node-positive patients (68.4%) had a lymph node dissection. Lymph node dissection rates declined from 2004 to 2018, 79.8% to 32.0% for clinically node-negative/pathologically node-positive patients and 80.4% to 61.2% for clinically node-positive/pathologically node-positive patients (both P < .0001). For clinically node-negative patients, lymph node surgery compliance improved from 63.7% (2004) to 70.4% (2018) (P < .0001). Compliance correlated with younger age, male sex, tumor mitotic rate, and site (extremity > trunk/head/neck) in multivariable analysis and improved 5-year cancer-specific survival (90.0% vs 83.4%) (all P < .0001). CONCLUSIONS: Despite clear guidelines, one-third of intermediate-thickness melanoma patients in a recent cohort did not have recommended lymph node surgery. Lymph node status is a key determinant of the relative benefit of adjuvant systemic therapy and the need for active surveillance of pathologically node-positive/clinically node-negative patients. These data highlighted a clinical care gap. Efforts to improve guideline compliance are a logical strategy to improve cancer outcomes for intermediate-thickness melanoma patients.
引用
- Piltin MA, Glasgow AE, Habermann EB, et al. Intermediate-thickness melanoma: A population-based study of surgical quality metrics. Surgery. 2022. PMID: 37534705. doi:10.1016/j.surg.2022.08.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。